FINAL RESULTS

About this update from Crism Therapeutics Corporation

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.     26 June 2026   CRISM THERAPEUTICS CORPORATION ('CRISM', the 'Company' or the 'Group')   FINAL RESULTS   'Regulatory milestones achieved and well-funded to advance Phase 2 Clinical Trial'   CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces its final audited results for the year ended 31 December 2025 (the 'year'). The Annual Report is available to view on the Company's website at www.crismtherapeutics.com and copies will be mailed to shareholders shortly.   Highlights: ·    MHRA Clinical Trial Authorisation ('CTA') received in September 2025, authorising the initiation of CRISM's open-label, registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma ·    Advance the preclinical development of docetaxel-ChemoSeed for the treatment of prostate cancer, supported by non-dilutive grant funding, further demonstrating ChemoSeed's potential as a platform technology across a broader range of solid tumour indications ·    Two equity fundraises completed during the year, raising a combined total of approximately £1.93 million (before expenses): a June 2025 placing and retail offer raising £874,021 to fund GMP manufacture of the clinical trial batch, and a December 2025 placing and retail offer raising approximately £1.06 million to progress Phase 2 trial preparation ·    R&D expenditure of £908,000, reflecting the Company's increased investment in clinical and pre-clinical development activities ahead of Phase 2 trial commencement ·      Total assets of £1.79 million (FY2024: £1.81 million) and cash of £1.13 million as at 31 December 2025 ·     Loss for the year of £1.90 million (FY2024: £0.61 million), reflecting the planned step-up in operational and R&D activity.   Post period end: ·   FDA Orphan Drug ...

View stock analysis, news, and events for Crism Therapeutics Corporation